Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: La Jolla Pharmaceutical
Deal Size: $132.0 million Upfront Cash: $22.5 million
Deal Type: Licensing Agreement January 12, 2021